• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

能够有效利用缺乏酪氨酸硫酸化氨基末端的CCR5的1型人类免疫缺陷病毒变体在gp120中存在适应性突变,包括功能性N-聚糖的缺失。

Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.

作者信息

Platt Emily J, Shea Danielle M, Rose Patrick P, Kabat David

机构信息

Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, OR 97239-3098, USA.

出版信息

J Virol. 2005 Apr;79(7):4357-68. doi: 10.1128/JVI.79.7.4357-4368.2005.

DOI:10.1128/JVI.79.7.4357-4368.2005
PMID:15767436
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1061536/
Abstract

By selecting the R5 human immunodeficiency virus type 1 (HIV-1) strain JR-CSF for efficient use of a CCR5 coreceptor with a badly damaged amino terminus [i.e., CCR5(Y14N)], we previously isolated variants that weakly utilize CCR5(Delta18), a low-affinity mutant lacking the normal tyrosine sulfate-containing amino-terminal region of the coreceptor. These previously isolated HIV-1(JR-CSF) variants contained adaptive mutations situated exclusively in the V3 loop of their gp120 envelope glycoproteins. We now have weaned the virus from all dependency on the CCR5 amino terminus by performing additional selections with HeLa-CD4 cells that express only a low concentration of CCR5(Delta18). The adapted variants had additional mutations in their V3 loops, as well as one in the V2 stem (S193N) and four alternative mutations in the V4 loop that eliminated the same N-linked oligosaccharide from position N403. Assays using pseudotyped viruses suggested that these new gp120 mutations all made strong contributions to use of CCR5(Delta18) by accelerating a rate-limiting CCR5-dependent conformational change in gp41 rather than by increasing viral affinity for this damaged coreceptor. Consistent with this interpretation, loss of the V4 N-glycan at position N403 also enhanced HIV-1 use of a different low-affinity CCR5 coreceptor with a mutation in extracellular loop 2 (ECL2) [i.e., CCR5(G163R)], whereas the double mutant CCR5(Delta18,G163R) was inactive. We conclude that loss of the N-glycan at position N403 helps to convert the HIV-1 envelope into a hair-trigger form that no longer requires strong interactions with both the CCR5 amino terminus and ECL2 but efficiently uses either site alone. These results demonstrate a novel functional role for a gp120 N-linked oligosaccharide and a high degree of adaptability in coreceptor usage by HIV-1.

摘要

通过选择R5型人类免疫缺陷病毒1型(HIV-1)毒株JR-CSF,以高效利用氨基末端严重受损的CCR5共受体[即CCR5(Y14N)],我们之前分离出了一些变体,这些变体对CCR5(Delta18)的利用较弱,CCR5(Delta18)是一种低亲和力突变体,缺乏共受体正常的含酪氨酸硫酸酯的氨基末端区域。这些之前分离出的HIV-1(JR-CSF)变体含有仅位于其gp120包膜糖蛋白V3环中的适应性突变。现在,我们通过用仅表达低浓度CCR5(Delta18)的HeLa-CD4细胞进行额外筛选,使病毒不再依赖CCR5氨基末端。适应性变体在其V3环中有额外的突变,以及V2茎中的一个突变(S193N)和V4环中的四个替代突变,这些突变消除了N403位置相同的N-连接寡糖。使用假型病毒的实验表明,这些新的gp120突变都通过加速gp41中依赖CCR5的限速构象变化,而不是通过增加病毒对这种受损共受体的亲和力,对CCR5(Delta18)的利用做出了重要贡献。与这种解释一致,N403位置V4 N-聚糖的缺失也增强了HIV-1对细胞外环2(ECL2)中存在突变的另一种低亲和力CCR5共受体的利用[即CCR5(G163R)],而双突变体CCR5(Delta18,G163R)无活性。我们得出结论,N403位置N-聚糖的缺失有助于将HIV-1包膜转变为一种触发式形式,这种形式不再需要与CCR5氨基末端和ECL2都有强烈相互作用,而是单独使用任何一个位点都能有效利用。这些结果证明了gp120 N-连接寡糖的一种新的功能作用以及HIV-1在共受体使用方面的高度适应性。

相似文献

1
Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.能够有效利用缺乏酪氨酸硫酸化氨基末端的CCR5的1型人类免疫缺陷病毒变体在gp120中存在适应性突变,包括功能性N-聚糖的缺失。
J Virol. 2005 Apr;79(7):4357-68. doi: 10.1128/JVI.79.7.4357-4368.2005.
2
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.动力学因素控制着人类免疫缺陷病毒的细胞进入效率、进入抑制剂的效力以及适应机制。
J Virol. 2005 Apr;79(7):4347-56. doi: 10.1128/JVI.79.7.4347-4356.2005.
3
Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.gp120 V3 环中的适应性突变增强了人类免疫缺陷病毒 1 型的融合能力,并使其能够利用缺乏氨基末端硫酸化区域的 CCR5 共受体。
J Virol. 2001 Dec;75(24):12266-78. doi: 10.1128/JVI.75.24.12266-12278.2001.
4
An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations.HIV-1 gp120中的变构变阻器降低了膜融合所需的CCR5化学计量,并克服了多种进入限制。
J Mol Biol. 2007 Nov 16;374(1):64-79. doi: 10.1016/j.jmb.2007.09.016. Epub 2007 Sep 12.
5
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.HIV-1包膜蛋白V3环截短赋予对共受体抑制剂的抗性并增强对中和抗体的敏感性。
PLoS Pathog. 2007 Aug 24;3(8):e117. doi: 10.1371/journal.ppat.0030117.
6
Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.酪氨酸硫酸化肽可逆且高效地激活 HIV-1 细胞进入,揭示了内吞进入和抑制剂作用机制。
J Virol. 2014 Apr;88(8):4304-18. doi: 10.1128/JVI.03447-13. Epub 2014 Jan 29.
7
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.人类免疫缺陷病毒1型(HIV-1)对进入抑制剂的敏感性与包膜/共受体亲和力、受体密度及融合动力学相关。
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. doi: 10.1073/pnas.252469399. Epub 2002 Nov 20.
8
Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.突变增加了 HIV-1 包膜糖蛋白 gp41 的融合后构象稳定性,被 X4 和 R5 HIV-1 病毒选择以逃避针对 gp41 七肽重复 1 的融合抑制剂,但两种病毒的 gp120 适应性突变不同。
J Virol. 2019 May 15;93(11). doi: 10.1128/JVI.00142-19. Print 2019 Jun 1.
9
Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.临床对维立西洛耐药的 HIV-1 亚型 D gp120 中的适应性 V3 环突变,这些突变改变了与 CCR5 的 N 端和 ECL2 的相互作用。
Virology. 2010 Apr 25;400(1):145-55. doi: 10.1016/j.virol.2010.01.037. Epub 2010 Feb 21.
10
Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.人类免疫缺陷病毒1型糖蛋白120 V3环在决定共受体使用中的作用。
AIDS Res Hum Retroviruses. 1999 May 20;15(8):731-43. doi: 10.1089/088922299310827.

引用本文的文献

1
Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.改变的 Env 构象动力学作为对肽-三唑 HIV-1 失活剂产生耐药性的机制。
Retrovirology. 2021 Oct 9;18(1):31. doi: 10.1186/s12977-021-00575-z.
2
Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.动力学因素的复杂相互作用决定了HIV-1进入抑制剂的协同特性。
J Biol Chem. 2017 Oct 6;292(40):16498-16510. doi: 10.1074/jbc.M117.791731. Epub 2017 Jul 10.
3
Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.HIV-1包膜糖蛋白受体激活导致gp41三聚体不对称暴露。
PLoS Pathog. 2016 Dec 19;12(12):e1006098. doi: 10.1371/journal.ppat.1006098. eCollection 2016 Dec.
4
Short Communication: HIV-1 Variants That Use Mouse CCR5 Reveal Critical Interactions of gp120's V3 Crown with CCR5 Extracellular Loop 1.简短通讯:利用小鼠CCR5的HIV-1变体揭示了gp120的V3冠与CCR5细胞外环1的关键相互作用。
AIDS Res Hum Retroviruses. 2015 Oct;31(10):992-8. doi: 10.1089/AID.2015.0131. Epub 2015 Aug 5.
5
Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.趋化因子受体5拮抗剂马拉维若可增强融合蛋白FLSC IgG1与趋化因子受体5的结合。
Antiviral Res. 2014 Dec;112:80-90. doi: 10.1016/j.antiviral.2014.10.006. Epub 2014 Oct 24.
6
Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.酪氨酸硫酸化肽可逆且高效地激活 HIV-1 细胞进入,揭示了内吞进入和抑制剂作用机制。
J Virol. 2014 Apr;88(8):4304-18. doi: 10.1128/JVI.03447-13. Epub 2014 Jan 29.
7
Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance.HIV-1 包膜基因可变区的突变可能对马拉维若和维克瑞韦罗的耐药性产生重大影响。
AIDS Res Ther. 2013 Jun 7;10(1):15. doi: 10.1186/1742-6405-10-15.
8
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.人类免疫缺陷病毒 1 型分离物对小分子 CCR5 抑制剂的耐药性可能涉及 gp120 和 gp41 中的序列变化。
Virology. 2011 Apr 25;413(1):47-59. doi: 10.1016/j.virol.2010.12.052. Epub 2011 Feb 26.
9
Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.HIV 逃避 CCR5 单克隆抗体的新机制:表位转换。
Antimicrob Agents Chemother. 2010 Feb;54(2):734-41. doi: 10.1128/AAC.00841-09. Epub 2009 Dec 7.
10
Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.人类免疫缺陷病毒1型包膜中有利于使用CCR5的组织特异性序列改变有助于双嗜性病毒在大脑中的持续存在。
J Virol. 2009 Jun;83(11):5430-41. doi: 10.1128/JVI.02648-08. Epub 2009 Mar 25.

本文引用的文献

1
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.动力学因素控制着人类免疫缺陷病毒的细胞进入效率、进入抑制剂的效力以及适应机制。
J Virol. 2005 Apr;79(7):4347-56. doi: 10.1128/JVI.79.7.4347-4356.2005.
2
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.抗体结构域交换是一种用于碳水化合物簇识别的免疫学解决方案。
Science. 2003 Jun 27;300(5628):2065-71. doi: 10.1126/science.1083182.
3
Antibody neutralization and escape by HIV-1.HIV-1的抗体中和作用与逃逸
Nature. 2003 Mar 20;422(6929):307-12. doi: 10.1038/nature01470.
4
T cell dynamics in HIV-1 infection.HIV-1感染中的T细胞动态变化
Annu Rev Immunol. 2003;21:265-304. doi: 10.1146/annurev.immunol.21.120601.141053. Epub 2001 Dec 19.
5
The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.HIV-1外膜糖蛋白gp120的V3环内的N-连接聚糖g15影响共受体使用、细胞嗜性和中和作用。
Virology. 2002 Dec 5;304(1):70-80. doi: 10.1006/viro.2002.1760.
6
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.HIV-1通过受体结合位点的构象掩盖来逃避抗体介导的中和作用。
Nature. 2002 Dec 12;420(6916):678-82. doi: 10.1038/nature01188.
7
CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5.CD4结合位点抗体可抑制人类免疫缺陷病毒gp120包膜糖蛋白与CCR5的相互作用。
J Virol. 2003 Jan;77(1):713-8. doi: 10.1128/jvi.77.1.713-718.2003.
8
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.人类免疫缺陷病毒1型(HIV-1)对进入抑制剂的敏感性与包膜/共受体亲和力、受体密度及融合动力学相关。
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. doi: 10.1073/pnas.252469399. Epub 2002 Nov 20.
9
Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.单个糖蛋白120聚糖的添加可增强与树突状细胞特异性细胞间黏附分子3结合非整合素的结合,并使1型人类免疫缺陷病毒产生中和逃逸。
J Virol. 2002 Oct;76(20):10299-306. doi: 10.1128/jvi.76.20.10299-10306.2002.
10
Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region.酪氨酸硫酸化肽在功能上重构了一个缺乏关键氨基末端区域的CCR5变体。
J Biol Chem. 2002 Oct 25;277(43):40397-402. doi: 10.1074/jbc.M206784200. Epub 2002 Aug 14.